Scientific Symposium at Med-Tech World Summit Malta
Vatic, a UK-based healthtech company, has received UK regulatory approval with a CE mark for it’s ‘breakthrough’ saliva ‘on-the-spot’ rapid COVID-19 test.
Hailed for it’s easy-to-use function, Vatic is pioneering the future of antigen tests with their 15 minutes ‘on-the-spot’ saliva COVID-19 test. The technology proves favorable over the more invasive nasopharyngeal or nasal swabs currently used in workplaces and schools.
The test could be a game-changer for UK businesses, and the company is currently working with major UK and global consumer retail, transport and hospitality brands in bid to pioneer the technology into the real-world.
Alex Sheppard, Vatic CEO and co-inventor of the technology, said:
CE Mark registration is a significant stage in rolling out this UK-based technology to help keep people safe and open closed sections of society. We are delighted to be trialling the technology with some of the UK’s most famous brands and institutions to help them keep their customers and employees safe.
We’ve seen in government-run studies that the accuracy of tests decline when experts aren’t involved. One reason is the sampling technique – it’s currently very difficult to get right and produce a good quality sample. The new generation of rapid antigen tests use saliva sampling – which is a lot easier to get right, a lot more comfortable so people will be more likely to comply, plus accuracy is less of a problem.
With the rise of multiple mutations across the world, vaccinations alone are no longer the silver bullet for ending the pandemic. Instead, regular testing and vaccine technologies are needed together to help reduce the overall spread and reopen society such as theatres, sporting and other cultural events, while helping to keep people safe from the virus. Regular, accessible COVID-19 infectivity screening is needed for us to do many of the things we are currently missing out on even with vaccines. Our much-loved social institutions and services can reopen safely such as schools, stadiums, airports, seaports, train stations, pubs and restaurants. Any company interested in trialling this technology please get in touch.
Vatic co-founder, co-inventor of the technology and chief technology officer, Dr Mona Kab Omir, added:
The more we can encourage and enable regular testing across the population – giving people clarity about whether they are infected (and, critically, infectious) – the quicker our lives will start to look more ‘normal’. Where a typical antigen test identifies the presence of harmless viral matter, our test identifies the infectiousness of the people who are tested. This is a much-needed technological breakthrough where in public health in it is critical to delineate.
See also: MicrosensDx rapid COVID-19 test receives CE mark
Source: Med-Tech Innovation News
Royal College of Surgeons and the National College of Art and Design partner to develop a silicone heart model